{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:48:48Z","timestamp":1785527328759,"version":"3.56.0"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is seen frequently in rheumatoid arthritis (RA); its often asymptomatic course delays diagnosis. Non-invasive scores and circulating biomarkers may enhance early detection. This study evaluated the prevalence of MASLD, the diagnostic performance of fatty liver index (FLI), hepatic steatosis index (HSI), and selected organokines (fatty acid binding protein 4, brain-derived neurotrophic factor, fetuin-A, and fibroblast growth factor 21) and explored associations of FLI and HSI with organokines, neutrophil-to-lymphocyte ratio, cardiovascular risk scores, and echocardiographic parameters of left ventricular diastolic dysfunction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This cross-sectional, exploratory study included 51 patients with RA (46 women; mean age 48.8\u00a0\u00b1\u00a08.2 years; median disease duration 12 years). The diagnostic value of liver fat scores and organokines for MASLD was assessed by receiver operating characteristic curve analysis. Associations between liver fat scores and organokines, neutrophil-to-lymphocyte ratio, cardiovascular risk scores, and left ventricular diastolic dysfunction parameters were analyzed using univariable linear regression, while relationships with MASLD were evaluated by logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>MASLD was detected in approximately one-third of participants. FLI and fatty acid binding protein 4 demonstrated the best diagnostic discrimination for MASLD in patients with RA [area under the curve (AUC) values of 0.81 and 0.82; Youden index 0.52 and 0.56; cut-off 18.7 and 24.01 ng\/mL; sensitivity 93% and 67%, specificity 58% and 89%, respectively]. FLI was positively associated with cardiovascular risk scores and left ventricular diastolic dysfunction parameters. Neutrophil-to-lymphocyte ratio was significantly associated with an increased MASLD risk (OR 2.53, p = 0.03).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The FLI and HSI showed moderate-to-good discrimination for ultrasound-defined MASLD, with FLI yielding a numerically higher AUC but without statistically significant superiority over HSI. The FLI showed better performance than the HSI in reflecting cardiovascular risk and abnormalities in left ventricular diastolic function parameters. FABP4 and FGF21 were associated with MASLD-related measures and may warrant further investigation as adjunctive biomarkers. The low exploratory FLI threshold and the association between NLR and MASLD require confirmation in larger, externally validated cohorts using more accurate liver fat quantification and adequately adjusted models.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1850882","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:51:43Z","timestamp":1780030303000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Liver steatosis, selected organokines, and cardiovascular risk markers in rheumatoid arthritis"],"prefix":"10.3389","volume":"17","author":[{"given":"Mariusz","family":"Cio\u0142kiewicz","sequence":"first","affiliation":[{"name":"Department of Rehabilitation, Medical University of Bialystok","place":["Bialystok, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kuryliszyn-Moskal","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation, Medical University of Bialystok","place":["Bialystok, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Jab\u0142o\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Immunology, Medical University of Bialystok","place":["Bialystok, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wioletta","family":"Ratajczak-Wrona","sequence":"additional","affiliation":[{"name":"Department of Immunology, Medical University of Bialystok","place":["Bialystok, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Janica","sequence":"additional","affiliation":[{"name":"Department of Radiology, Medical University of Bialystok","place":["Bialystok, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W\u0142odzimierz","family":"Samborski","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Rehabilitation and Internal Diseases, Poznan University of Medical Sciences","place":["Poznan, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr A.","family":"Klimiuk","sequence":"additional","affiliation":[{"name":"Internal Medicine, Medical University of Bialystok","place":["Bialystok, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.5114\/reum.2020.99782","article-title":"Liver involvement in rheumatic diseases","volume":"58","author":"Podg\u00f3rska","year":"2020","journal-title":"Reumatologia"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2174\/1573397115666191007121605","article-title":"Etiological features of liver involvement in rheumatoid arthritis","volume":"16","author":"Sellami","year":"2020","journal-title":"Curr Rheumatol Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.15003","article-title":"Antirheumatic drugs and the risk of nonalcoholic fatty liver disease in patients with rheumatoid arthritis: a nationwide, population-based cohort study","volume":"27","author":"Meng","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ejim.2023.08.002","article-title":"Clinical features and immune mechanisms directly linked to the altered liver function in patients with rheumatoid arthritis","volume":"118","author":"Arias-de la Rosa","year":"2023","journal-title":"Eur J Intern Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000043641","article-title":"Prevalence of nonalcoholic fatty liver disease in rheumatoid arthritis: an updated systematic review and meta-analysis","volume":"104","author":"Mahapatro","year":"2025","journal-title":"Med (Baltimore)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1759720X211042739","article-title":"Prevalence and risk factors of moderate to severe hepatic steatosis in patients with rheumatoid arthritis: an ultrasonography cross-sectional case\u2013control study","volume":"13","author":"Erre","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00296-025-06002-2","article-title":"Rheumatoid arthritis is independently associated with metabolic dysfunction-associated steatotic liver disease: evidence from the Paracelsus 10,000 population-based cohort study","volume":"45","author":"Ausserwinkler","year":"2025","journal-title":"Rheumatol Int"},{"key":"B8","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J Hepatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.155800","article-title":"Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: a community-dwelling cohort study with 20-year follow-up","volume":"153","author":"Choe","year":"2024","journal-title":"Metabolism"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.15.04003","article-title":"Association of steatotic liver disease with all-cause and cardiovascular mortality among prehypertensive or hypertensive patients","volume":"15","author":"Yan","year":"2025","journal-title":"J Glob Health"},{"key":"B11","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4093\/dmj.2024.0042","article-title":"Metabolic dysfunction-associated steatotic liver disease and all-cause and cause-specific mortality","volume":"49","author":"Oh","year":"2025","journal-title":"Diabetes Metab J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15939","article-title":"Impact of MASLD and MetALD on clinical outcomes: a meta-analysis of preliminary evidence","volume":"44","author":"Ciardullo","year":"2024","journal-title":"Liver Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.884636","article-title":"Association between metabolic dysfunction-associated fatty liver disease and cardiovascular risk in patients with rheumatoid arthritis: a cross-sectional study of Chinese cohort","volume":"9","author":"Zou","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.125.325492","article-title":"Decoding the liver-heart axis in cardiometabolic diseases","volume":"136","author":"Capone","year":"2025","journal-title":"Circ Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2023.01.006","article-title":"The role of hepatokines in NAFLD","volume":"35","author":"Stefan","year":"2023","journal-title":"Cell Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1663353","article-title":"The endocrine role of hepatokines: implications for human health and disease","volume":"16","author":"Iglesias","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1007944","article-title":"Regulatory network and interplay of hepatokines, stellakines, myokines and adipokines in nonalcoholic fatty liver diseases and nonalcoholic steatohepatitis","volume":"13","author":"Yang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13081854","article-title":"Adipokine and hepatokines in metabolic dysfunction-associated steatotic liver disease (MASLD): current and developing trends","volume":"13","author":"Pezzino","year":"2025","journal-title":"Biomedicines"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2337\/dbi23-0005","article-title":"Adipose signals regulating distal organ health and disease","volume":"73","author":"Gilani","year":"2024","journal-title":"Diabetes"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116104","article-title":"The role of novel adipokines and adipose-derived extracellular vesicles (ADEVs): connections and interactions in liver diseases","volume":"222","author":"Xie","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.781789","article-title":"Relationship between fatty acid binding protein 4 and liver fat in individuals at increased cardiometabolic risk","volume":"3","author":"Rodr\u00edguez-Calvo","year":"2021","journal-title":"Front Physiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10010197","article-title":"Unveiling the role of the fatty acid binding protein 4 in the metabolic-associated fatty liver disease","volume":"10","author":"Moreno-Vedia","year":"2022","journal-title":"Biomedicines"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/antiox13111363","article-title":"Myokines and their potential protective role against oxidative stress in metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"13","author":"Bucarey","year":"2024","journal-title":"Antioxidants (Basel)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4081\/ejtm.2025.13365","article-title":"Impact of myokines on chronic liver diseases: exploring the effects of metabolic dysfunction-associated steatotic liver disease (MASLD) on skeletal muscle. A narrative review","volume":"35","author":"Aguirre","year":"2025","journal-title":"Eur J Transl Myol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2024.101534","article-title":"Association between nonalcoholic fatty liver disease and left ventricular diastolic dysfunction: a 7-year retrospective cohort study of 3,380 adults using serial echocardiography","volume":"50","author":"Kim","year":"2024","journal-title":"Diabetes Metab"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.935390","article-title":"Association of metabolic dysfunction-associated fatty liver disease with left ventricular diastolic function and cardiac morphology","volume":"13","author":"Peng","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14248844","article-title":"Neutrophil-to-lymphocyte ratio and fibroblast growth factor 21: their role in early cardiovascular involvement in rheumatoid arthritis","volume":"14","author":"Cio\u0142kiewicz","year":"2025","journal-title":"J Clin Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584","article-title":"Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score","volume":"7","author":"Aletaha","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease","volume":"42","author":"Lee","year":"2010","journal-title":"Dig Liver Dis"},{"key":"B31","unstructured":""},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-6-33","article-title":"The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"B33","unstructured":""},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"key":"B35","unstructured":""},{"key":"B36","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1002\/art.39195","article-title":"Derivation and internal validation of an expanded cardiovascular risk prediction score for rheumatoid arthritis: a Consortium of Rheumatology Researchers of North America Registry Study","volume":"67","author":"Solomon","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B37","unstructured":""},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"B39","unstructured":""},{"key":"B40","unstructured":""},{"key":"B41","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J AmSoc Echocardiogr"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2025.1571487","article-title":"Assessment of the diagnostic efficacy of five non-invasive tests for MASLD: external validation utilizing data from two cohorts","volume":"12","author":"Zou","year":"2025","journal-title":"Front Nutr"},{"key":"B43","doi-asserted-by":"publisher","first-page":"62","DOI":"10.37349\/eemd.2024.00008","article-title":"Four hepatic steatosis indices in predicting quantitative computed tomography-based metabolic dysfunction-associated fatty liver disease","volume":"1","author":"Xu","year":"2024","journal-title":"Explor Endocr Metab Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12070664","article-title":"Comparison of the diagnostic performance of steatosis indices for discrimination of CT-diagnosed metabolic dysfunction-associated fatty liver disease","volume":"12","author":"Han","year":"2022","journal-title":"Metabolites"},{"key":"B45","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/RHU.0000000000001980","article-title":"Risk factors and clinical outcomes associated with sarcopenia in rheumatoid arthritis: a systematic review and meta-analysis","volume":"30","author":"Tam","year":"2024","journal-title":"J Clin Rheumatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2025.e43073","article-title":"Comparing non-alcoholic fatty liver disease indices in predicting the prevalence and incidence of metabolic syndrome in middle-aged adults","volume":"11","author":"Kim","year":"2025","journal-title":"Heliyon"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13735","article-title":"Circulating level of fatty acid-binding protein\u20094 is an independent predictor of metabolic dysfunction-associated fatty liver disease in middle-aged and elderly individuals","volume":"13","author":"Tanaka","year":"2022","journal-title":"J Diabetes Investig"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1850882\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T04:51:46Z","timestamp":1780030306000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1850882\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":47,"alternative-id":["10.3389\/fendo.2026.1850882"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1850882","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"article-number":"1850882"}}